SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Revance Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

761330109

(CUSIP Number)

09/30/2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

761330109

Names of Reporting Persons

Patrick Lee, MD

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,611,787.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,611,787.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,611,787.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

1.54 %

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No.

761330109

Names of Reporting Persons

Anthony Joonkyoo Yun, MD

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,611,787.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,611,787.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,611,787.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

1.54 %

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No.

761330109

Names of Reporting Persons

Palo Alto Investors LP

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,611,787.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,611,787.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,611,787.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

1.54 %

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No.

761330109

Names of Reporting Persons

PAI LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,611,787.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,611,787.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,611,787.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

1.54 %

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Revance Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

1222 Demonbreun Street, 20th Floor, Nashville, TN, 37203

Item 2.

(a)

Name of person filing:

Palo Alto Investors LP ("PAI") PAI LLC ("PAI GP") Patrick Lee, MD Anthony Joonkyoo Yun, MD (collectively, the "Filers").

(b)

Address or principal business office or, if none, residence:

The address of the principal place of the Filers is located at: 470 University Avenue, Palo Alto, CA 94301

(c)

Citizenship:

For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

(d)

Title of class of securities:

Common Stock

(e)

CUSIP No.:

761330109

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

See Item 9 of the cover page for each Filer.

(b)

Percent of class:

See Item 11 of the cover page for each Filer for

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Item 5 of the cover page for each Filer.

(ii) Shared power to vote or to direct the vote:

See Item 6 of the cover page for each Filer.

(iii) Sole power to dispose or to direct the disposition of:

See Item 7 of the cover page for each Filer.

(iv) Shared power to dispose or to direct the disposition of:

See Item 8 of the cover page for each Filer.

Item 5.

Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

PAI is a registered investment adviser and investment adviser of investment limited partnerships, and is the investment adviser to other investment funds. PAI GP is the general partner of investment limited partnerships. PAI's clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

Dr. Lee and Dr. Yun co-manage PAI. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each of them expressly disclaims membership in a group. Each Filer disclaims beneficial ownership of the Stock except to the extent of that Filer's pecuniary interest therein.

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Patrick Lee, MD

Signature:	Patrick Lee, MD
Name/Title:	Patrick Lee, MD
Date:	01/10/2025

Anthony Joonkyoo Yun, MD

Signature:	Anthony Joonkyoo Yun, MD
Name/Title:	Anthony Joonkyoo Yun
Date:	01/10/2025

Palo Alto Investors LP

Signature:	Angela Nguyen-Dinh
Name/Title:	Angela Nguyen-Dinh, Chief Compliance Officer
Date:	01/10/2025

PAI LLC

Signature:	Patrick Lee, MD
Name/Title:	Patrick Lee, MD, Managing Member
Date:	01/10/2025

Exhibit Information

EXHIBIT A GREEMENT FOR JOINT FILING OF SCHEDULE 13G

Amendment: SEC Form SCHEDULE 13G/A filed by Revance Therapeutics Inc.